NCT03552926 (DHU-LAC) is a clinical trial in Lacunar Strokes, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT03552926?

NCT03552926 is sponsored by Assistance Publique - Hôpitaux de Paris.

What condition does NCT03552926 study?

NCT03552926 studies Lacunar Strokes.

Is NCT03552926 still recruiting?

NCT03552926 is currently recruiting now. Last updated 2 May 2022.

Last reviewed 2022-05-02 · How we verify

NCT03552926: DHU-LAC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Constitution of a Clinico-radiological Database and a Biobank for Patients With Lacunar Infarcts

Recruiting now Last updated 2 May 2022

What this trial tests

trial in Lacunar Strokes in 500 participants. Currently enrolling.

Timeline

6 June 2018

Primary endpoint
30 August 2022

30 August 2027

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	500
Start date	6 June 2018
Primary completion	30 August 2022
Estimated completion	30 August 2027
Sites	1 location across France

Conditions studied

Lacunar Strokes — all drugs for Lacunar Strokes →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Lacunar Strokes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to determine in patients with a recent lacunar strokes (\<15 days), the natural history of cognitive disturbances and disability.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

MRI-Proven Incident Ischemia: A New Marker of Disease Progression in Small Vessel Diseases.
Grosset L, Dimitrovic A, Guillonnet A, Tamazyan R, et al · · 2025 · cited 6× · PMID 39569496 · DOI 10.1161/strokeaha.124.048046
Prevalence of anxiety and depression following small subcortical ischemic stroke and their association with MRI-defined brain damage: The DHU-LAC cohort study.
Dimitrovic A, Jabouley A, Machado C, de Sanctis MH, et al · · 2025 · PMID 41438306 · DOI 10.1016/j.cccb.2025.100521

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03552926 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 2 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03552926.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing